Trump Administration proposes new Medicare rule to lower prescription drug costs

Trump Admin Proposes Medicare Rule to Cut Drug Costs

Theindiapostdaily.com – On July 2, the Trump administration unveiled a new Medicare rule aimed at reducing prescription drug expenses for beneficiaries. The proposal targets hospitals participating in the 340B Drug Pricing Program, which currently allows them to purchase medications at steep discounts. By aligning Medicare reimbursements with these lower costs, the policy seeks to save an estimated $1.1 billion for patients in 2025. This initiative is part of the administration’s broader effort to address rising healthcare costs and ensure more affordable access to essential medications.

Reimbursement Rates and the 340B Program

The Trump administration’s plan centers on the 340B Drug Pricing Program, a federal initiative that enables qualifying hospitals to acquire drugs at reduced prices. These hospitals, often serving low-income communities, can then pass on the savings to patients. However, under the current system, Medicare reimburses hospitals at rates far higher than the discounted prices they pay. This discrepancy creates a financial gap that hospitals have historically used to offset their costs, sometimes passing the burden to patients through higher co-payment fees. The new rule aims to correct this imbalance.

How the System Works and the Proposed Changes

Presently, hospitals enrolled in the 340B Program purchase drugs at significantly lower prices, yet Medicare pays them at much higher rates. This difference allows hospitals to retain profits, which are then often added to patients’ out-of-pocket costs. The Trump administration’s proposal would cap Medicare reimbursements at the Average Sales Price (ASP) minus 33.4%, as mandated by an executive order from President Donald Trump in April 2025. This adjustment could reduce Medicare payments by roughly 40%, directly impacting the amount patients are required to pay for their medications.

Anticipated Savings and Benefits for Patients

Analysts predict that Medicare Part B beneficiaries using 340B drugs could save approximately $800 annually in co-payments. Over the next decade, total patient savings could reach $20 billion if the policy remains in effect. The administration argues that this shift would make prescription medications more accessible, particularly for vulnerable populations, while also ensuring that hospitals are not overpaid for drugs they acquire at discounted rates. Such changes are framed as critical steps toward long-term healthcare affordability.

Challenges and Opposition from Hospitals

While the Trump administration’s plan highlights potential cost savings for patients, hospitals have raised concerns about its financial impact. The American Hospital Association warned that reduced reimbursements could strain hospital budgets, especially in rural and underserved areas. Ashley Thompson, a senior vice president at the association, emphasized,

“This proposal would weaken hospitals’ capacity to deliver critical care and sustain affordable access for vulnerable patients.”

Critics argue that lower payments might force hospitals to cut services or raise other costs, potentially undermining the very affordability the policy aims to achieve.

Historical Context and the 340B Program’s Role

Established in 1992, the 340B Drug Pricing Program was designed to help hospitals serving low-income populations access discounted medications. Over the years, it has become a key tool in reducing healthcare costs for underserved communities. However, the program has also sparked debates about its effectiveness and sustainability. The Trump administration’s rule change seeks to redefine the program’s role by limiting Medicare reimbursements to better reflect the actual drug prices hospitals pay, thus addressing perceived inefficiencies in the current system.

Implementation and Future Implications

The proposed rule is expected to be finalized and implemented by the Centers for Medicare & Medicaid Services (CMS) in the coming months. If enacted, it would mark a significant shift in how Medicare funds hospitals for drug-related services. Advocates believe the policy will enhance transparency and accountability in reimbursement practices. However, the success of the rule will depend on its ability to balance cost savings for patients with the financial stability of hospitals. The administration’s strategy underscores its commitment to lowering prescription drug costs, but the long-term effects remain to be seen.